Markus Siegelin, MD

Board Certifications: 
Anatomic Pathology
Accepting New Patients
Profile Headshot

Overview

MD, 2005 - Johann-Wolfgang-Goethe University, Frankfurt am Main Germany

2006-2007 Intern in Neurology - Ruprecht-Karls-University, Heidelberg, Germany.

2007 - 2009 Fellowship Neuropathology - Ruprecht-Karls-University, Heidelberg, Germany. Post-Doctoral

2009-2010 Research Fellowship - University of Massachusetts

Residency in Anatomic Pathology - New York Presbyterian Hospital, Columbia University Medical Center, College of Physicians and Surgeons

Email: ms4169@cumc.columbia.edu

Academic Appointments

  • Associate Professor of Pathology & Cell Biology

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • German

Gender

  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, 2005 Johann Wolfgang Goethe University Faculty of Medicine (Germany)
  • 2005 Johann Wolfgang Goethe University Medical School
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Ruprecht Karl University (Germany)

Board Certifications

  • Anatomic Pathology

Honors & Awards


2007 Rudi-Busse Dissertation Award for the best doctoral thesis in 2007, Johann-Wolfgang-Goethe University, Frankfurt am Main, Germany

2007 Young Investigator Award, Ruprecht-Karls-University, Heidelberg, Germany

2009 Post-Doctoral Research Fellowship awarded by German Research Foundation.

2012 Stowell-Orbison Award, United States & Canadian Academy of Pathology, Vancouver, BC, Canada.

2013 American Association for Cancer Research (AACR) and National Brain Tumor Society Career Development Award for Translational Brain Tumor Research

2013 Translational Grant Program, American Brain Tumor Association (ABTA)

2014-2019 National Institue of Health, NINDS, K08 Career Development Award

2016-2021 National Institue of Health, NINDS, R01 Research Grant

2016 BCURED Fighting Brain Cancer Award

Research

Research Interests

  • Establishing Mechanisms of Drug Resistance in Brain Tumors
  • Identification of Novel Drug Combination Therapies for Brain Tumors
  • Targeting Cell Death Mechanisms in Brain Tumors
  • Targeting Tumor Cell Metabolism and The Epigenome for Brain Tumor Therapy

Grants

TARGETING MUTANT IDH1 FOR A NOVEL SYNTHETIC LETHAL INTERACTION IN MALIGNANT GLIOMAS (Federal Gov)

May 15 2018 - Feb 28 2023

LXR AGONISTS COMBINED WITH BH3-MIMETICS AS A NOVEL TREATMENT FOR GLIOBLASTOMA (Private)

Aug 15 2019 - Aug 14 2021

DUAL INHIBITION OF MITOCHONDRIAL MATRIX CHAPERONES AND ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS FOR GLIOBLASTOMA THERAPY. (Federal Gov)

Aug 1 2016 - Jul 31 2021

OVERCOMING APOPTOTIC RESISTANCE IN GLIOBLASTOMA BY CP-D/N-ATF5, A NOVEL TUMOR SPECIFIC THERAPEUTIC COMPOUND TARGETING THE TRANSCRIPTION FACTOR ATF5 (Federal Gov)

Aug 1 2014 - Jun 30 2019

OVERCOMING APOPTOTIC RESISTANCE IN GLIOBLASTOMA BY CP-D/N-ATF5, A NOVEL TUMOR SPECIFIC THERAPEUTIC COMPOUND TARGETING THE TRANSCRIPTION FACTOR ATF5 (Federal Gov)

Aug 1 2014 - Jun 30 2019

INDUCTION OF SYNTHETIC LETHALITY IN IDH1 MUTATED GLIOMAS (Private)

Jun 15 2017 - Jun 14 2018

INDUCTION OF SYNTHETIC LETHALITY IN IDH1 MUTATED GLIOMAS (Private)

Jun 15 2016 - Jun 14 2017

CP-D/NATF5 AS A NOVEL POTENT TREATMENT FOR MALIGNANT GLIOMA (Private)

Jul 1 2013 - Jun 30 2015

CP-DNATF5 IN COMBINATION WITH PROAPOPTOTIC AGONISTS AS A NOVEL POTENT TREATMENT FOR MALIGANANT GLIOMA (Private)

Jul 1 2013 - Jun 30 2014

Selected Publications

Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.

Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res. 2017 Jul 1;77(13):3513-3526. doi: 10.1158/0008-5472.CAN-16-3424. Epub 2017 May 18

Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget. 2016 Jun 7;7(23):33512-28. doi: 10.18632/oncotarget.9257.

Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Siegelin MD. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Clin Cancer Res. 2016 Sep 15;22(18):4698-711. doi: 10.1158/1078-0432.CCR-15-2827.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.

Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget. 2015 Nov 3;6(34):36456-71. doi: 10.18632/oncotarget.5505.

Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, Lisanti S, Rampini P, Giroda M, Caino MC, Seo JH, Kossenkov AV, Michalek RD, Schultz DC, Bosari S, Languino LR, Altieri DC. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju502. doi: 10.1093/jnci/dju502.

Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, Siegelin MD. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res. 2014 Jul;12(7):987-1001. doi: 10.1158/1541-7786.MCR-13-0650.

Siegelin MD. Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer? Cancer letters. (2013). Jun 10;333(2):133-46.

Siegelin, M.D. Utilization of the cellular stress response to sensitize cancer cells to TRAIL - mediated apoptosis. Expert Opin Ther Targets. (2012). 16(8): 801-17.

Siegelin, M. D., T. Dohi, C. M. Raskett, G. M. Orlowski, C. M. Powers, C. A. Gilbert, A. H. Ross, J. Plescia and D. C. Altieri. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. (2011). 121(4): 1349-60.

Ghosh, J. C., M. D. Siegelin, T. Dohi and D. C. Altieri. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. (2010). 70(22): 8988-93.

Kang, B. H., M. D. Siegelin, J. Plescia, C. M. Raskett, D. S. Garlick, T. Dohi, J. B. Lian, G. S. Stein, L. R. Languino and D. C. Altieri. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. (2010). 16(19): 4779-88.

Elias, A., M. D. Siegelin, A. Steinmuller, A. von Deimling, U. Lass, B. Korn and W. Mueller. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res. (2009). 15(17): 5457-65.